Bryan Supran
Director/Board Member en ANACOR PHARMACEUTICALS INC .
Fortuna: 210 395 $ al 31/03/2024
Perfil
Bryan Supran is currently the Director & Vice President at Array BioPharma, Inc., the Director at Anacor Pharmaceuticals LLC, the Non-Executive Director at Haleon Plc, and the Senior Vice President & Deputy General Counsel at Pfizer Inc. He previously worked as a Director at Medivation LLC (California), Viatris, Inc., and Haleon UK Holdings (No.2) Ltd.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
HALEON PLC
0.00% | 31/12/2023 | 50 000 ( 0.00% ) | 210 395 $ | 31/03/2024 |
Cargos activos de Bryan Supran
| Empresas | Cargo | Inicio |
|---|---|---|
| ANACOR PHARMACEUTICALS INC | Director/Board Member | 24/06/2016 |
| ARRAY TECHNOLOGIES, INC. | Director/Board Member | 30/07/2019 |
| HALEON PLC | Director/Board Member | 18/07/2022 |
| PFIZER, INC. | General Counsel | 01/04/2016 |
Antiguos cargos conocidos de Bryan Supran.
| Empresas | Cargo | Fin |
|---|---|---|
Haleon UK Holdings (No.2) Ltd.
 Haleon UK Holdings (No.2) Ltd. Financial ConglomeratesFinance Part of Haleon Plc, Haleon UK Holdings (No.2) Ltd. is an investment holding private company. Haleon UK Holdings (No.2) Ltd. is based in Weybridge, UK. Founded in 2019, Haleon UK Holdings (No.2 functions as an investment holding company. | Director/Board Member | 18/07/2022 |
| VIATRIS INC. | Director/Board Member | 16/11/2020 |
| MEDIVATION INC | Director/Board Member | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| VIATRIS INC. | Health Technology |
| HALEON PLC | Distribution Services |
| Empresas privadas | 4 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Medivation LLC (California)
 Medivation LLC (California) Pharmaceuticals: MajorHealth Technology Medivation LLC engages in the development and commercialization of novel therapies to treat serious diseases for which there are limited treatment options. The company was founded by Clarence Patrick Machado and David T. Hung in 2004 and is headquartered in San Francisco, CA. | Health Technology |
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Haleon UK Holdings (No.2) Ltd.
Haleon UK Holdings (No.2) Ltd. Financial ConglomeratesFinance Part of Haleon Plc, Haleon UK Holdings (No.2) Ltd. is an investment holding private company. Haleon UK Holdings (No.2) Ltd. is based in Weybridge, UK. Founded in 2019, Haleon UK Holdings (No.2 functions as an investment holding company. | Finance |
- Bolsa de valores
- Insiders
- Bryan Supran
